Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Biagio De Angelis

Has grant

Dirigente Farmacista

Ospedale Pediatrico Bambino Gesù

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Recent Grants

Grant: Open

New therapeutics targets with clinical intervention for both paediatric and adult Brain cancer

Open Date: 2024-05-01

Close Date: 2029-04-01

Grant: Open

Development of next-generation CAR T cells targeting both osteosarcoma and tumor microenvironment

Open Date: 2024-01-01

Close Date: 2029-01-01

Grant: Close

Generazione di cellule T geneticamente modificate con un recettore chimerico antigenico (CAR) specifico per il recettore 1 del folato (CAR.FOLR1) e CXCR2 per la massima efficacia antitumorale nell’ Osteosarcoma

Open Date: 2024-01-01

Close Date: 2024-12-01

Grant: Close

CAR T cells for treating CD19+, CD20+ or CD22+ tumors

Open Date: 2024-01-01

Close Date: 2024-12-01

Grant: Close

The ACC preclinical research platform for precision oncology

Open Date: 2022-01-01

Close Date: 2023-06-01

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Clemens Zwergel

Tenure-track Assistant Professor RTT

Sapienza University of Rome

ITALY

View details

Luca Simula

Permanent Researcher (CRCN INSERM)

Institut Cochin

FRANCE

View details

Ignazio Caruana

Group Leader - Scientific Research

University Hospital Würzburg

GERMANY

View details

Alessandro FANZANI

Associate Professor in Biochemistry

University of Brescia

ITALY

View details

Silvia Pomella

RTT

University of Rome Tor Vergata

ITALY

View details

Rossella Rota

Group Leader

Ospedale Pediatrico Bambino Gesù

ITALY

View details

Ernesto Guccione

Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Biagio De Angelis

Research Interests

Explore related searches

Recent Grants

Articles (20)

An in vivo CRISPR screen unveils promising target genes to improve CAR-T cell efficacy in a solid tumor model.

From Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery

CD19 antigen: from tumor target to safety switch in CAR-T cell therapy

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma

European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring

GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial

GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system

Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3–FOXO1 rhabdomyosarcoma

Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse

Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case report

Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial (Nature Medicine, (2025), 31, 11, (3689-3699), 10.1038/s41591-025-03874-6)

Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ∆CD19

HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks

GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma

Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells

MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57<sup>Kip2</sup> targeting

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL

Collaborators (7)

Clemens Zwergel

Luca Simula

Ignazio Caruana

Alessandro FANZANI

Silvia Pomella

Rossella Rota

Ernesto Guccione

Make your next move.